Cabot Corporation $CBT Stock Position Increased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its stake in Cabot by 5.0% to 1,556,762 shares (about 2.93% ownership), valuing its position at roughly $118.4 million, and institutional investors own about 93.18% of the company.
• Cabot reported an EPS beat of $1.53 vs. $1.40 consensus while revenue fell 11.1% year‑over‑year; management set FY2026 guidance of $6.00–$6.50 EPS versus analyst expectations around $7.57.
• Cabot declared a quarterly dividend of $0.45 ($1.80 annual, ~2.7% yield) and trades at a market cap of $3.54 billion with a PE of 11.87 and a 52‑week range of $58.33–$85.64.

Dimensional Fund Advisors LP increased its position in Cabot Corporation (NYSE:CBT - Free Report) by 5.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,556,762 shares of the specialty chemicals company's stock after buying an additional 73,734 shares during the quarter. Dimensional Fund Advisors LP owned about 2.93% of Cabot worth $118,392,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC raised its position in Cabot by 598.0% in the third quarter. Smartleaf Asset Management LLC now owns 349 shares of the specialty chemicals company's stock worth $27,000 after acquiring an additional 299 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Cabot during the 2nd quarter valued at about $28,000. Parkside Financial Bank & Trust grew its stake in shares of Cabot by 95.5% in the 2nd quarter. Parkside Financial Bank & Trust now owns 387 shares of the specialty chemicals company's stock worth $29,000 after purchasing an additional 189 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of Cabot by 227.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 429 shares of the specialty chemicals company's stock worth $33,000 after purchasing an additional 298 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Cabot by 409.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 364 shares in the last quarter. Institutional investors own 93.18% of the company's stock.

Cabot Stock Performance

Shares of CBT opened at $67.78 on Thursday. The company has a market capitalization of $3.54 billion, a PE ratio of 11.87, a PEG ratio of 9.06 and a beta of 0.86. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.09 and a current ratio of 1.67. The company's 50 day moving average price is $73.03 and its 200 day moving average price is $71.19. Cabot Corporation has a 52 week low of $58.33 and a 52 week high of $85.64.

Cabot (NYSE:CBT - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The specialty chemicals company reported $1.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.13. Cabot had a net margin of 8.62% and a return on equity of 22.82%. The company had revenue of $849.00 million during the quarter, compared to analyst estimates of $889.11 million. During the same quarter last year, the business posted $1.76 EPS. The company's revenue for the quarter was down 11.1% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-6.500 EPS. Research analysts expect that Cabot Corporation will post 7.57 EPS for the current fiscal year.

Cabot Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Friday, February 27th will be given a dividend of $0.45 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $1.80 dividend on an annualized basis and a yield of 2.7%. Cabot's dividend payout ratio (DPR) is presently 31.52%.

Wall Street Analyst Weigh In

Several analysts recently commented on CBT shares. Zacks Research raised shares of Cabot from a "strong sell" rating to a "hold" rating in a research note on Tuesday, January 27th. Mizuho set a $75.00 price target on Cabot and gave the company a "neutral" rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. reduced their price objective on Cabot from $75.00 to $54.00 and set an "underweight" rating for the company in a research note on Friday, November 28th. UBS Group boosted their target price on Cabot from $74.00 to $81.00 and gave the stock a "neutral" rating in a research report on Thursday, February 5th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Cabot in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cabot currently has an average rating of "Hold" and an average price target of $73.75.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Corporation (NYSE:CBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.